IQVIA

Fundamental to the success of your market access strategy is clear visibility into payer, provider and patient behavior. IQVIA’s comprehensive real-world database includes lifecycle transactions, which offer the critical level of detail required to untangle the complex interaction of payer utilization mana...

Powered by the IQVIA CORE™, our promotional analysis can help you understand the trajectory of your brand and measure its progress along the way. We can help you see where you are today, where you’re going and help you make adjustments as part of your path forward. Find out what you need to know about •...

Faster market access by optimized clinical trials Every study is unique and stakes are high. In order to ensure success IQVIA uses all available resources - therapeutical expertise, latest technology, advanced analytics and proactive approach. This allows us to effectively search for research centers an...

Even if your objective seems clear–demonstrate the value of your product – it is rarely a simple task. That is because there is no single story or piece of evidence when you speak to audiences around the world: regulators, health technology assessment (HTA) bodies, payers, providers and patients. IQVIA ...

Each launch has a million moving pieces. Almost all are based on what you know about your market. Which patients are using which products? What is their patient journey? What types of physicians prescribe them? How do treatments and costs vary by geography or provider? Primary market research provides some...

CPHI has launched its forward-looking pharma trend report for 2022 and it is now available to read on CPHI Online.

CPHI is back in Frankfurt, an important hub for the German pharmaceutical community. This session will explore the German market and look at the abundance of innovation emerging from one of Europe's biggest pharma hubs.
This session will touch upon: Access to Innovative Medicines and Launch Performance Developments in Generics and Biosimilars Initiatives Towards Further Digitalization Did you enjoy this session? If so, you might like to visit our Connect to Frankfurt platform, where you can browse our collection of 30+ on-demand webinars and learn about our upcoming CPHI Frankfurt event, taking place 1-3 November in Frankfurt, Germany.
Bringing together the global supply chain under one roof, CPHI Frankfurt puts you at the heart of pharma. Can’t attend in person? You can access many of the event offerings online! Browse our exhibitor list, arrange meetings, view on-site content and network – all from home.

Click here to register

In this webinar, originally broadcast as part of the Pharmapack Europe show, speaker Aurelio Areas, Engagement Manager, IQVIA will give us a look at the global outlook of the pharma industry as it emerges from the pandemic with a focus on drug delivery trends. This session analyses current dynamics in drug delivery devices and look at emerging growth areas such as the rise of self-administration, connectivity and the impact of devices on our environment.

In this webinar, originally broadcast as part of the Pharmapack Europe show, Stefan Lutzmayer, Consultant, IQVIA discusses how as biologics and specialty medicines increase in importance in global healthcare, especially when access to medicines and biosimilars become growth areas, this brings various opportunities in developing the logistical network that delivers these medicines to patients in a temperature-controlled environment. This session explores the rapid growth of cold-chain medicines and seek to understand their impact on health provision and the environment.

Rapid climate change has direct impacts on human health. These arise from multiple causes, including severe weather, changing ecology of disease vectors, increased allergens, and geopolitical conflict over scarce resources.
Healthcare itself contributes to climate change because of its sizeable carbon footprint. It follows that health systems should be frontrunners in reducing its carbon footprint to limit the impact of climate change and mitigate poorer health outcomes and inequity.
Many health systems have identified medicines as one of the largest single contributors to their carbon footprint. This session will evaluate the pharma industry’s carbon footprint and provide recommendations on what we can do to reduce emissions, meet environmental targets, and consequently open a new path to supporting human health.